Pharmacology

It's often the case that when something claims to cure everything, a little skepticism is warranted. We have dozens of articles here on Resveratrol but over time the titles began to reflect growing disbelief it could be that perfect. By the time it ...

Article - Hank Campbell - Aug 1 2012 - 10:52am

Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory In All Vaccinees

BERN, Switzerland, January 17, 2012 /PRNewswire/-- Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vac ...

Article - Newswire - Jan 17 2012 - 12:30pm

Niiki Pharma Announces The Completion Of Phase I Dose Escalation For First-in-Man Anti-Cancer Agent NKP-1339

HOBOKEN, New Jersey and PHILADELPHIA, January 17, 2012 /PRNewswire/--- Trial Demonstrates Favorable Safety Profile with Anti-Tumor Activity Niiki Pharma Inc. announced today that it has completed the dose escalation portion of the Phase I clinical trial o ...

Article - Newswire - Jan 17 2012 - 1:30pm

Memory: Even Decaffeinated Coffee Is Awesome

It may turn out that coffee is bad for you. The World Health Organization already lists it as a possible carcinogen, despite any evidence, but they do the same thing about cell phones, in contrast to any evidence- perhaps Big Tea donates a lot to WHO. Unti ...

Article - News Staff - Feb 1 2012 - 2:01pm

Genetic Modification Plus Big Pharm Equals Anti-Science Hippie Meltdown

What's the one thing that could make anti-science progressives dislike genetic modifications and medicine even more than they do now? Putting them both together. ...

Article - Hank Campbell - Feb 24 2012 - 1:04am

Berries Benefit Brains?

Evidence suggests that eating blueberries, blackberries, strawberries and other berry fruits has beneficial effects on the brain and may help prevent age-related memory loss and other changes, scientists report. In a new review, Barbara Shukitt-Hale, Ph. ...

Article - News Staff - Mar 8 2012 - 8:00am

Results From Study Of Eisai's Investigational Epilepsy Treatment Perampanel

Eisai today announces the publication of results from a pivotal Phase III study of perampanel, an investigational, highly selective, non-competitive AMPA-type glutamate receptor antagonist developed as an adjunctive therapy for partial seizures in adult p ...

Article - Newswire - Apr 18 2012 - 5:46pm

New Data Suggests Interferon-Free Therapy Around The Corner For HCV Patients

Further data shows PegIFN-lambda's comparable efficacy but better safety profile than PegIFN-alpha New data presented at the International Liver Congress(TM) 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The mu ...

Article - Newswire - Apr 21 2012 - 2:30am

Additional Benefit Of Eribulin For Metastatic Or Locally Advanced Breast Cancer Confirmed

The German Federal Joint Committee (G-BA), the supreme decision-making body of the self-governing medical system in Germany, announced that it considers the use of Halaven(R) (eribulin) to have additional benefit versus comparative treatments, defined by ...

Article - Newswire - Apr 20 2012 - 11:00am

ONO-4641 Reduced Number Of Multiple Sclerosis Lesions In Phase II Trial

ONO-4641, an investigational oral drug, reduced the number of lesions in people with multiple sclerosis (MS), according to the results of a phase two clinical trial to be presented this week at the American Academy of Neurology Meeting in New Orleans. ...

Article - News Staff - Apr 23 2012 - 4:03am